- Home
- TBLA vs XERS Comparison
TBLA vs XERS Comparison
Compare TBLA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBLA | XERS |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | 2000 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 952.2M | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TBLA | XERS |
|---|---|---|
| Price | $4.93 | $6.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $5.00 | ★ $10.83 |
| AVG Volume (30 Days) | ★ 2.9M | 1.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $7.63 | $34.37 |
| Revenue Next Year | $5.25 | $22.86 |
| P/E Ratio | ★ $42.36 | $638.48 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $2.84 | $4.30 |
| 52 Week High | $5.26 | $10.08 |
Technical Indicators
Market Signals| Indicator | TBLA | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 68.93 | 49.57 |
| Support Level | $3.86 | $5.79 |
| Resistance Level | $5.26 | $6.41 |
| Average True Range (ATR) | 0.26 | 0.32 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 77.26 | 28.51 |
Price Performance
Historical ComparisonAbout TBLA Taboola.com Ltd.
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.